EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease

Busra Cetin iD, Melike Aliciaslan iD, Ezgi Erbasan iD, Busra Cesur Ergun iD, Salih Sanlioglu iD

Expert Reviews in Molecular Medicine · 2026

DOI: 10.1017/erm.2026.10072 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, 2026. Verfasst von Busra Cetin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Türkiye. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Precision Medicine. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Spinal Muscular Atrophy (SMA) is caused by a deficiency of the survival motor neuron (SMN) protein due to loss of SMN1 and inefficient compensation by SMN2. This genetic architecture has driven the development of precision therapeutics. Over the past decade, SMA management has progressed from supportive care to RNA-based splicing modulation and gene replacement therapy.

Methods

This review analyzes the evolution of three therapeutic waves in SMA management: antisense oligonucleotides (nusinersen) for SMN2 splicing correction; systemic small-molecule splicing modifiers (risdiplam) addressing SMA as a multisystem disorder; and gene replacement therapy (onasemnogene abeparvovec), including recent intrathecal formulations expanding patient eligibility.

Results

Precision therapies have profoundly altered the disease trajectory, especially when administered presymptomatically. Nusinersen sustains splicing correction, risdiplam restores SMN across central and peripheral tissues, and gene replacement offers durable, one-time genetic correction. However, critical challenges persist regarding therapeutic durability, optimal treatment sequencing, systemic involvement, and long-term safety.

Conclusions

The evolution of SMA therapies has transformed neurogenetics. Clinical benchmarks have successfully shifted from reactive, symptomatic management to proactive, molecularly targeted precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalPrecision MedicineHumansGenetic TherapyAnimalsOligonucleotidesOligonucleotides, AntisenseSurvival of Motor Neuron 2 ProteinSurvival of Motor Neuron 1 ProteinGene Therapy AgentsRNA SplicingAzo CompoundsPyrimidines

Stichwörter der Autor:innen

Itvismagene therapynusinersenonasemnogene abeparvovecrisdiplamspinal muscular atrophyzolgensma

Substanzen

OligonucleotidesnusinersenOligonucleotides, AntisenseSurvival of Motor Neuron 2 ProteinSurvival of Motor Neuron 1 ProteinRisdiplamSMN2 protein, humanAzo CompoundsPyrimidines

Autor:innen und Institutionen

  • Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Türkiye.

ORCID-Profile: Busra Cetin, Melike Aliciaslan, Ezgi Erbasan, Busra Cesur Ergun, Salih Sanlioglu

Zitieren

APA

Cetin, B., Aliciaslan, M., Erbasan, E., Cesur Ergun, B., & Sanlioglu, S. (2026). Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease. Expert Reviews in Molecular Medicine. https://doi.org/10.1017/erm.2026.10072

Vancouver

Cetin B, Aliciaslan M, Erbasan E, Cesur Ergun B, Sanlioglu S. Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease. Expert Reviews in Molecular Medicine. 2026. doi:10.1017/erm.2026.10072

BibTeX
@article{Cetin2026,
  author = {Cetin, Busra and Aliciaslan, Melike and Erbasan, Ezgi and Cesur Ergun, Busra and Sanlioglu, Salih},
  title = {Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease},
  journal = {Expert Reviews in Molecular Medicine},
  year = {2026},
  doi = {10.1017/erm.2026.10072}
}
Kostenlos starten →